Enterprise Value
1.282B
Cash
166.1M
Avg Qtr Burn
-15.32M
Short % of Float
15.26%
Insider Ownership
2.36%
Institutional Own.
52.68%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Afrezza® (insulin human) Inhalation Powder Details Diabetes, Type 1 diabetes, Type 2 diabetes | Approved Quarterly sales | |
Tyvaso DPI (Treprostinil Technosphere®) (inhaled treprostinil) Details Pulmonary arterial hypertension, Heart disease | Approved Quarterly sales | |
Afrezza® (insulin human) Inhalation Powder Details Type 1 diabetes, Diabetes, Type 2 diabetes | Phase 3 Data readout | |
Clofazimine inhalation suspension (MNKD 101) Details Nontuberculous mycobacterial lung disease, Lung disease | Phase 2/3 Initiation |